Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clini
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:36am, Wednesday, 12'th Mar 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
10:20pm, Tuesday, 11'th Mar 2025
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
06:25pm, Monday, 10'th Mar 2025
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data re
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 10'th Mar 2025
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
01:50pm, Monday, 10'th Mar 2025
On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or r
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
01:09pm, Monday, 10'th Mar 2025
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday.
Mineralys Therapeutics' blood pressure drug meets goal in trials
07:12am, Monday, 10'th Mar 2025
Mineralys Therapeutics said on Monday its blood pressure drug, lorundrostat, met the main goal in late- and mid- stage trials.
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed b
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
01:38pm, Wednesday, 12'th Feb 2025
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
07:00am, Wednesday, 12'th Feb 2025
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k
